U.S. Markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.68 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.58 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.39 (-0.61%)
     
  • Gold

    1,777.30
    +10.50 (+0.59%)
     
  • Silver

    26.04
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1980
    +0.0004 (+0.0359%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3842
    +0.0058 (+0.4180%)
     
  • USD/JPY

    108.7900
    +0.0740 (+0.0681%)
     
  • BTC-USD

    62,067.50
    +273.97 (+0.44%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

Celsion's Ovarian Cancer Immunotherapy Shows 38% Improvement In R0 Resection Rates Versus Control Arm

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Celsion Corporation (NASDAQ: CLSNreports interim observations and provides an update on its Phase 1/2 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 3/4 ovarian cancer.

  • GEN-1 is a DNA-mediated interleukin-12 (IL-12) immunotherapy.

  • The OVATION 2 study combines GEN-1 with standard-of-care neoadjuvant chemotherapy. NACT is designed to shrink cancer as much as possible for optimal surgical removal after three chemotherapy cycles.

  • Celsion has enrolled 34 of the anticipated 110 patients, from which 20 are in the treatment arm and 14 are in control.

  • 12 of 15 patients treated with GEN-1 had an R0 resection, which indicates a microscopically margin-negative complete resection in which no gross or microscopic tumor remains in the tumor bed.

  • 7 of 12 patients in the control arm had an R0 resection.

  • Enrollment in the study to complete during the second half of 2021.

  • Earlier this week, CLSN stock rallied after GEN-1 received Fast Track Designation for advanced ovarian cancer.

  • Price Action: CLSN at up 1.23% at $2.33 in market trading hours on the last check Thursday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.